This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Avi Kapoor 8 months ago
NewsDowngradesPre-Market OutlookAnalyst RatingsTrading Ideas
Wall Street analysts changed ratings on top stocks. Check out analyst ratings page for full list. NVO downgraded from Buy to Neutral with $41 target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- RBC Capital analyst Brian Abrahams downgraded Aardvark Therapeutics Inc (NASDAQ:AARD) from Outperform to Sector Perform and cut the price target from $18 to $6. Aardvark Therapeutics shares closed at $12.49 on Friday. See how other analysts view this stock.
- BTIG analyst Marvin Fong downgraded Fiverr International Ltd (NYSE:FVRR) from Buy to Neutral. Fiverr Intl shares closed at $10.83 on Friday. See how other analysts view this stock.
- Morgan Stanley analyst Michael Ulz downgraded Aardvark Therapeutics Inc (NASDAQ:AARD) from Overweight to Equal-Weight and slashed the price target from $29 to $7. Aardvark Therapeutics shares closed at $12.49 on Friday. See how other analysts view this stock.
- Goldman Sachs analyst James Quigley downgraded Novo Nordisk A/S (NYSE:NVO) from Buy to Neutral and cut the price target from $63 to $41. Novo Nordisk shares closed at $37.45 on Friday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating for Aardvark Therapeutics Inc (NASDAQ:AARD) from Buy to Neutral. Aardvark Therapeutics shares closed at $12.49 on Friday. See how other analysts view this stock.
Considering buying NVO stock? Here’s what analysts think:
Photo via Shutterstock